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BACKGROUND: We aimed to discuss the risk assessments for both patients with hip fractures due to fall-related, low energy 
traumas and non-fractured control patients by examining bone mineral density and genetic data, two features associated with 
femoral strength and hip fracture risk. 
METHODS: Twenty-one osteoporotic patients with proximal femur fractures and non-fractured, osteoporotic, age- and gender-
matched controls were included in the study. Bone mineral density measurements were performed with a Lunar DXA. The COL1A1, 
ESR, VDR, IL-6, and OPG genes were amplified, and labeling of specific gene sequences was performed in a multiplex polymerase 
chain reaction using the osteo/check PCR kit from the whole blood of all subjects. 
RESULTS: The bone mineral density (trochanteric and total bone mineral density values) of the fracture group was significantly 
decreased relative to the control group. We were not able to conduct statistical tests for the polymorphisms of the COL1A1, ESR, 
and VDR genes because our results were expressed in terms of frequency. Although they were not significant, we did examine 
differences in the IL-6 and OPG genes polymorphisms between the two groups. We concluded that increasing the number of cases 
will allow us to evaluate racial differences in femoral hip fracture risk by genotypes.
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INTRODUCTION
Proximal femoral fractures occur in both genders of 
the aging population as a result of osteoporosis as well as 
decreasing bone strength. The vast majority of hip fractures 
result from fall-related minor trauma to the proximal 
femur. Today, the most important approach to preventing 
this widespread, clinical problem involves the evaluation 
of bone strength and determination of fracture risks.1-4 The 
pathogenesis of osteoporosis is complex, and is determined 
by the interaction of genetic, metabolic, and multiple 
environmental factors. 
All risk factors can be evaluated alone or together with 
bone mineral density (BMD) values; moreover, they can 
be combined for fracture risk assessment. Age and gender 
are two factors that affect the fracture risk independently of 
BMD values.2,5 
Genes have an important functional effect on bone 
metabolism and growth. Moreover, osteoporosis and hip 
fractures also appear to be under genetic control.6 Osteoporosis 
is polygenic in nature: multiple, common, polymorphic alleles 
interact both with one another and with environmental factors 
to determine bone mass.7 Rapid progress has been made in 
identifying the genes and alleles that may determine bone 
density in recent years, but little progress was achieved in 
identifying the genetic determinants of hip fracture risk.8 
Although different studies have reported a relationship 
between several candidate polymorphic genes and BMD, some 
were inconclusive. The results of such studies among different 
populations have been mostly inconsistent, suggesting genetic 
heterogeneity of osteoporosis. It is likely that the cohort of 
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genes indicating predisposition to the risk of osteoporosis may 
differ among populations with different ethnic backgrounds.7 
These different results could reflect ethnic or racial differences 
in genetic makeup. 
The genes under evaluation are those that code for major 
components of the bone matrix. Osteoporosis is strongly 
associated with Sp1 binding site polymorphisms in the first 
intron of the COL1A1 gene. This gene encodes collagen type 
1, an important component in the bone matrix.9,10
The G to T polymorphism in COL1A1’s first intron Sp1 
site causes increased binding affinity for Sp1 and increased 
levels of COL1A1 transcript.11 Alleles with a G-base at the 
Sp1 binding are defined as ‘S’, whereas alleles with a T-base 
are defined as ‘s’. Clinical studies in several populations 
have shown that patients with the ‘s’ allele are likely to have 
reduced BMD and osteoporotic fractures.12,13 
Estrogens also play an important role in regulating bone 
homeostasis, bone turnover, and the maintenance of bone 
mass. The skeletal effects of estrogen are mediated by its 
binding to two different receptors that are members of the 
nuclear receptor superfamily of ligand-activated transcription 
factors. The individual contribution of these polymorphisms 
for osteoporosis remains to be universally confirmed. The 
human estrogen receptors α (ESR1, chromosome 6q25) and 
α (ESR2, chromosome 14q23-24) are likely candidate genes 
for osteoporosis. Both isoforms are expressed in osteoblasts, 
osteoclasts, and bone marrow stromal cells.14
The vitamin D receptor (VDR) is a major regulator of 
calcium and bone metabolism, and was the first candidate 
gene to be studied in relation to osteoporosis. A substitution 
in the 3’-region of the vitamin D receptor gene has been 
described, and the b [A] and B [G] alleles differentiated via 
BsmI RFLP analysis. The BB genotype is associated with 
decreased VDR function and increased osteoporosis risk.15 
Osteoprotegerin (OPG), which is required for the 
maintenance of bone density, negatively regulates osteoclast 
differentiation and blocks pathophysiological induction of 
bone resorption by interacting with the receptor-activator 
of the nuclear factor kappa B ligand. The promoter region 
of the human OPG gene contains various binding sites that 
may mediate the stimulation of OPG gene expression.16,17 
Polymorphisms in this and other regions of the OPG gene 
may contribute to genetic control of bone mass.18-20 OPG and 
interleukin-6 (IL-6) are putative target genes for estrogen 
signaling and have been implicated both in cardiovascular 
diseases and osteoporosis.
In this study, we aimed to investigate the risk assessments 
of both patients with hip fractures and non-fractured, control 
patients by examining BMD values and possible allelic 
influences of the COL1A1, ESR, VDR, IL-6, and OPG 
genes. 
MATERIAL AND METHODS
Twenty-one osteoporotic patients with proximal femur 
fracture due to simple low-energy trauma falls (8 male, 13 
female, mean age 74.47 ± 8.91 years) were included in the 
study along with 21 osteoporotic volunteers with no history 
of fracture at any anatomic localization serving as age- and 
gender-matched controls. All subjects were of Turkish 
origin from different regions of Turkey. The study was 
approved by the Hospital Ethics Committee. No patients had 
neoplastic bone pathology, long-term corticosteroid usage, 
bone metabolism disease, or arthritis. Control subjects did 
not have any history of disease related to bone metabolism 
or structural integrity. In addition, we ensured that no fixed 
deformity or restricted joint movement was found in the 
fracture-free and radiologically-measured joints. 
Proximal femur bone mineral density measurements
BMD measurements were performed with a Lunar 
DXA for both fracture and control group patients. The 
measurements were taken from the intact side of the hip in 
the fracture group and from the right side of the hip in the 
control group. BMD measurements were obtained as femoral 
neck, Ward’s triangle, trochanteric, and total BMD values. 
Genotyping
Genomic DNA was extracted from whole blood samples 
using an Invisorb® Spin Blood Mini Kit according to the 
manufacturer’s instructions. The COL1A1, ESR, VDR, IL-
6, and OPG genes were amplified, and labeling of specific 
gene sequences was performed using biotinylated primers 
in a multiplex polymerase chain reaction (PCR) using the 
osteo/check PCR kit (The Ogham Diagnostic System). The 
PCR reaction included an initial activation step (15 min., 
95ºC), 3-step-cycling of 35 cycles (denaturing 1 min. at 
94ºC, annealing 2 min. 56ºC and elongation 1 min. 68ºC), 
and terminal elongation (5 min. at 68ºC and cooling to 
4ºC). Detection of amplified DNA sequences by means of 
allele-specific hybridization was done in the Array Tube®. 
Denatured PCR products were added onto the chip of 
the Array Tube®, and hybridization was performed with 
sequence-specific probes to distinguish between wild-type 
and mutated DNA sequences. After washing to remove the 
non-bound PCR products, free binding sites were blocked on 
the chip. Bound biotin-labeled PCR products were coupled 
with streptavidin-conjugate. After washing to remove non-
bound streptavidin, staining and densitometric detection 
were conducted in a solas 1 reader. Finally, an automatic 
calculation of patient genotypes was performed. 
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Data Analysis:
In both groups, mean ± standard deviation (SD) values 
were calculated for anthropometric data such as weight, 
height, BMI, and BMD. In order to establish a difference in 
these parameters between the two groups, an independent 
sampling test (t test) was then used. Parameters with values 
of p<0.05 were considered statistically significant. Results 
for the polymorphisms of the COL1A1, ESR, and VDR 
genes are given as frequencies, and Fisher’s Exact Test was 
used for tests of IL-6 and OPG gene polymorphisms. All 
statistical analysis was performed with the SPSS (Statistical 
Package for Social Sciences) for Windows v. 10 (SPSS Inc, 
Chicago, IL) program. 
RESULTS
The means and standard deviations for the anthropometric 
and BMD values for the fracture and control groups are listed 
in Table 1. There were no significant differences between 
the fracture and control groups with regard to age, weight, 
length, or BMI. BMI showed a slight but non-significant 
difference between the control and fracture groups. 
The average BMD values of the control group were 
higher than those of the fracture group in all anatomical 
regions. However, the difference was statistically significant 
only for the trochanteric and total BMD values (p=0.039 
and p=0.012 respectively). The differences for the neck and 
Ward’s BMD values were not significantly different between 
the two groups. 
The distributions of the COL1A1 gene Sp1 genotypes 
as well as the ESR1 gene PvuII and XbaI genotypes among 
patients and controls are shown in Table 2. The frequency of 
the COL1A1 gene SS genotype was higher than that of the 
ss genotype in both the fracture and control groups, whereas 
the frequency of the Ss heterozygote genotype in each 
group was similar or higher than that of either the SS or ss 
genotypes (57.9 vs. 45.0%, respectively). The frequencies 
of ESR1 PvuII (PP/pp) and XbaI (XX/xx) genotypes were 
similar in the fracture group (26.3 vs. 25.0%, respectively), 
but the frequencies of PP and XX were increased (40.0 vs. 
47.4% respectively) and pp and xx were decreased (20.0 vs. 
15.8% respectively) in the control group relative to fracture 
group. The Pp heterozygote frequencies accounted for 47.4% 
of the fracture group and 40% of the control group. Xx 
heterozygote frequencies accounted for 50% of the fracture 
group and 36.8% of the control group.
The distributions of the VDR gene BsmI genotypes 
among patients and controls are shown in Table 3. The 
frequency of the BB genotype was somewhat lower among 
Table 1 - Means and Standard Deviations of Anthropometric 
and Femoral Bone Mineral Density (BMD) Parameters in the 







Age (years) 74.47 ± 8.91 75.47 ± 7.44 0.695
Height (cm) 164.71 ± 8.28 160.66 ± 9.91
Weight (kg) 68.80 ± 12.45 70.95 ± 13.95
BMI 25.46 ± 4.82 27.36 ± 4.14 0.179
BMD parameters
Neck BMD (gr/cm2) 0.67 ± 0.09 0.67 ± 0.17 0.657
Wards BMD (gr/cm2) 0.51 ± 0.11 0.52 ± 0.19 0.450
Trochanter BMD (gr/cm2) 0.55 ± 0.07  0.64 ± 0.18 * 0.039
Total BMD (gr/cm2) 0.72 ± 0.09  0.84 ± 0.21 * 0.012
Significant results between two groups are noted with bold type and asterisks. 
(***p<0.05)
Table 2 - Distribution of COL1A1gene Sp1 as well as ESR 
gene PvuuII and XbaI polymorphisms in the two groups 
Patient Control
COL1A1 Sp1 n=19 % n=20 %
SS 5 26.3 9 45.0
Ss 11 57.9 9 45.0
ss 3 15.8 2 10.0
ESR 1 PvuII n=19 % n=20 %
PP 5 26.3 8 40.0
Pp 9 47.4 8 40.0
pp 5 26.3 4 20.0
ESR 1 XbaI n=16 % n=19 %
XX 4 25.0 9 47.4
Xx 8 50.0 7 36.8
xx 4 25.0 3 15.8
The restriction fragment length polymorphisms (RFLPs) were coded as Ss 
(Sp1), Pp (Pvull), and Xx (Xbal). The uppercase letter signifies absence of 
the site, and the lowercase letter signifies presence of the site.
Table 3 - Distribution of VDR gene BsmI polymorphism in 
patients and controls
Patient Control
VDR BsmI n=19 % n=21 %
BB 2 1.5 0 0.0
Bb 11 57.9 14 66.7
bb 6 31.6 7 33.3
The restriction fragment length polymorphisms (RFLPs) were coded as Bb 
(Bsm I), where the uppercase letter signifies presence of the site and the 
lowercase letter signifies absence of the site.
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fracture patients, whereas that of the Bb genotype was 
higher (BB: 1.5 vs. 0%; Bb: 57.9). The frequency of bb 
homozygotes was similar between fractured patients and 
controls (31.6 vs. 33.3%, respectively). 
The distributions of the OPG gene G209A and T245G as 
well as IL-6 gene G-174C polymorphisms among patients 
and controls are shown in Table 4. For OPG, the GG and TT 
genotypes were not observed in either group. The frequencies 
of the GA and TG genotypes were lower than those of the AA 
and GG genotypes, which showed the highest frequencies. 
No statistically significant differences were observed among 
these genotype between the fracture and control groups. For 
IL-6, the GC and CC genotypes had approximately equal 
frequencies within the groups. No statistically significant 
differences between groups were noted.
DISCUSSION 
Bone constantly undergoes remodeling to repair and 
replace existing bone tissue. In aging, the amount of 
bone tissue gradually declines as structural elements are 
lost. Osteoporotic proximal femur fractures are typically 
characterized by a decrease in bone strength below a 
threshold level. However, studies show that the risk of 
fracture formation in the trochanteric region increases 
markedly as the trochanteric BMD value decreases. This 
finding provoked us to hypothesize that the amount of bone 
mass loss, which is accompanied by a decrease in bone 
strength, is far more important than the increase in resistance 
resulting from cortical thickening.
Adaptive changes in proximal femoral anatomy are 
related to old age and decreased BMD. Other adaptive 
changes have been thought to arise from genetic properties 
regarding bone morphology and mineral distribution. These 
different adaptations result in different bone strengths and 
degrees of fracture formation risk. In order to establish a 
relationship between proximal femoral geometric parameters 
and fracture risk, more studies should be carried out on a 
broader and more ethnically diverse population. 
Although our study was limited in its statistical power 
to detecting differences in polymorphisms, we discussed 
the frequencies of polymorphisms and compared our results 
with others from the Turkish population which are limited 
to only a few studies. 
The COLIA1 Sp1 binding site polymorphism appears 
to be an important susceptibility allele for osteoporotic 
fractures. Results from studies in several populations and 
meta-analyses show that carriers of the s allele have an 
increased risk of fracture .21,22 This allele can predispose one 
to osteoporotic fractures by affecting bone strength through 
mechanisms that are partly independent of differences 
in BMD. A frequency distribution study on 111 healthy, 
postmenopausal Turkish women showed that seventy-
nine (71.2%) were homozygous for SS, 30 (27.0%) were 
heterozygous carrying Ss, and two (1.8%) were homozygous 
for ss. In our study, the ss and Ss frequencies were higher in 
the fracture group than the control group; accordingly, the 
SS frequency in the control group was higher than that in the 
fracture group (Table 2). Another study performed by Simsek 
et al. showed no significant differences between the COL1A1 
Table 4 - Distribution of OPG genes G209A and T245G as well as IL-6 gene G-174C polymorphisms in the groups
Patient Control  
OPG G209A n=19 % n=21 % p value
GG
GA 3 15.8 1 4.8 >0.05
AA 16 84.2 20 95.2 >0.05
polymorphism were termed GG, GA, and AA; G indicates the presence of the restriction site at -209 
OPG T245G n=20 % n=20 % p value
TT
TG 3 15.0 0 0 >0.05
GG 17 85.0 20 100 >0.05
polymorphism were termed TT, TG, and GG; T indicates the presence of the restriction site at -245 
IL-6 G-174C n=20 % n=17 % p value
GG
GC 10 50.0 7 41.2 >0.05
CC 10 50.0 10 58.8 >0.05
polymorphism were termed GG, GC, and CC; G indicates the presence of the restriction site at -174
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genotype groups in terms of age, months since menopause, 
weight, height, baseline BMD at the femoral neck, or lumbar 
spine. All patients in that study were osteopenic, with a T 
score of <2.5 SD.23
According to the meta-analysis of the estrogen receptor 
gene from different study groups, XX homozygotes for 
XbaI might have a higher BMD as well as a decreased risk 
of fractures in comparison to carriers of the x allele. In 
contrast, PvuII polymorphisms were not associated with 
either BMD or fracture risk.24 In our study, the XX frequency 
in the control group was higher than that in the fracture 
group (Table 2); however, we were not able to perform 
statistical tests. As we observed from another study of the 
Turkish population conducted by Yilmaz et al. with regard 
to coronary artery disease (CAD), a statistically significant 
relationship between the ESR1 c.454-397T>C (PvuuII) 
polymorphism and CAD was found to be independent of 
known CAD risk factors.25
VDR gene polymorphisms associated with osteoporosis, 
osteomalacia, breast cancer, hypocalcemia, and psoriasis 
have been reported in the Turkish population.26-30 Gunes et 
al. found no statistically significant differences in the allelic 
and genotypic frequencies of BsmI between patient (n=110) 
and control (n=150) groups. Similar to our findings, these 
authors also observed that the heterozygote genotype was 
the most frequent among both patients and controls (Table 
3).31 Our data regarding allelic frequencies were also similar 
to those found in other countries, including Denmark,32 
Slovenia,33 Brazil,34 and Italy.35 Those results may indicate a 
lack of correlation between BMD or fracture risk and VDR 
gene polymorphisms.
IL-6 is also a candidate cytokine that has been implicated 
in enhanced osteoclastogenesis, bone resorption, and 
accelerated bone loss. In our study, we did not observe any 
GG genotypes in either group. The GC and CC frequencies 
were equal, and statistically non-significant differences 
were reported between the groups. Budak et al. reported 
frequencies that differed from those in our study. In their 
control group of 50 healthy subjects, they observed 55.1% 
GG, 26.5% GC, and 18.4% CC polymorphisms.36 Moffett 
et al. analyzed the relationship between the IL-6 G-174C 
polymorphism and osteoporosis phenotypes in 3376 older 
women. Women with the CC genotype had a significantly 
slower rate of decline in hip BMD and a 33% lower risk of 
wrist fracture than women with the GG genotype. Variation 
at the IL-6 locus may contribute to genetic susceptibility to 
bone fragility.37 Additionally, Feng et al. suggested a negative 
relationship between femoral neck BMD and IL-6 levels in 
the CC genotype.38
Osteoprotegrin plays an important role as an inhibitor 
of osteoclast differentiation, and polymorphisms in the 
gene coding for OPG might influence the bone remodeling 
process. OPG could thus be a candidate gene for identifying 
individuals at risk for developing low bone mass or 
osteoporosis. The G to A substitution at position 209 and 
the T to G substitution at position 245 in the promoter region 
of the OPG gene have been well described. As with the 
IL-6 gene, we did not observe any statistically significant 
differences in the OPG gene between the fracture and control 
groups. Carriers of the G (for G209A) and T alleles (for 
T245G) have been found to be at risk for osteoporosis, but 
our study did not include any subjects homozygous for GG 
or TT. Subjects heterozygous for GA or TG were also rare 
(Table 4). Ohmori et al. found no evidence of a significant 
linkage between OPG and osteoporosis, but they did note the 
possible association of osteoporosis and a single-nucleotide 
polymorphism located in the promoter region of the gene.39
Due to multifactorial inheritance and influential 
environmental factors, the molecular-genetic basis of 
osteoporosis is currently not clearly understood. We hope 
that the differences in individual responsiveness to treatment, 
when clarified at the genomic level, will enable more 
effective, individualized guidance in clinical practice.
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